News
Research and company updates.
Follow Lucier’s scientific abstracts, presentations, milestones, and company updates.
Lucier research receives Best Abstract recognition at CTRS 2026
Dr. Guangrong Lu presented Lucier's coronary microcirculation research at the 2026 Clinical and Translational Research Symposium, where the work received Best Abstract recognition.
Read the announcement2026
Lucier selected for two October startup pitch competitions
Lucier has been selected for Startup World Cup Dallas and the LvlUp Ventures × Uber for Business pitch event. Dr. Guangrong Lu will also attend Chicago Venture Summit: Future of Health.
Lucier awarded $606,311 NIH grant to advance LU-1001 research
The National Heart, Lung, and Blood Institute has awarded Lucier Pharmaceuticals $606,311 to investigate the diagnostic and therapeutic potential of LU-1001 for coronary microvascular dysfunction (CMD).
Lucier research presented at Baylor’s 13th Annual CVRI Symposium
Dr. Guangrong Lu presented the team’s research on endothelin-1-induced coronary arteriolar constriction at Baylor College of Medicine’s 13th Annual Cardiovascular Research Institute Symposium.
Lucier research selected for presentation at ACC.26
Lucier's research on endothelin-1-induced coronary arteriolar constriction was selected for presentation at the American College of Cardiology's ACC.26 Scientific Session.
Lucier shares coronary arteriole research at SCCM Discovery
Dr. Guangrong Lu presented Lucier’s coronary arteriole research at the Society of Critical Care Medicine’s Discovery Critical Care Innovation Incubator in Chicago.
Lucier participates in Fort Worth innovation summit
Dr. Guangrong Lu represented Lucier at an academic and industry collaboration forum hosted by the Fort Worth–Tarrant County Innovation Partnership and Texas A&M–Fort Worth.
Dr. Lu attends the 2026 TARCC Scientific Symposium
Dr. Guangrong Lu attended the Texas Alzheimer’s Research and Care Consortium’s 2026 Scientific Symposium, joining researchers and clinicians in Austin.
Lucier selected for four 2026 bootcamp and accelerator programs
Lucier’s 2026 milestones include the SCCM Discovery Critical Care Innovation Incubator, Nucleate Activator’s Texas program, LA BioStart, and a Harvard Business School Foundry bootcamp.
2025
Lucier research on ROCK2-mediated coronary arteriolar constriction presented at AHA 2025
Abstract 4335925, published in Circulation, examines clinically relevant endothelin-1 concentrations and ROCK2-mediated constriction in porcine coronary arterioles.
Coronary arteriole research makes its public debut at ET-19
The Nineteenth International Conference on Endothelin marked the first public disclosure of the team’s findings on endothelin-1-induced coronary arteriolar constriction.
Lucier joins the Texas life science community at BioNTX iC3
Dr. Guangrong Lu attended BioNTX’s 2025 iC3 Life Science & Healthcare Innovation Summit in Dallas, marking his first business conference.
Dr. Lu participates in Startup Prize 2025
Dr. Guangrong Lu participated in Startup Prize in 2025, adding entrepreneurship training to Lucier’s early company development.